Lyell Immunopharma (LYEL) Expected to Announce Earnings on Monday

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Trading Down 1.9 %

Shares of LYEL stock traded down $0.01 during trading on Friday, hitting $0.46. The company's stock had a trading volume of 491,707 shares, compared to its average volume of 1,042,424. The company has a market cap of $136.21 million, a PE ratio of -0.58 and a beta of -0.26. The business has a fifty day moving average of $0.53 and a 200-day moving average of $0.71. Lyell Immunopharma has a 52 week low of $0.39 and a 52 week high of $2.88.

Insider Transactions at Lyell Immunopharma

In other news, CFO Charles W. Newton acquired 200,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $0.56 per share, with a total value of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Lynn Seely acquired 175,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the purchase, the chief executive officer now directly owns 712,500 shares in the company, valued at $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 768,640 shares of company stock worth $449,508 in the last quarter. Insiders own 25.10% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.